Related Experiment Video
Updated: Jun 28, 2026

Expression, Detergent Solubilization, and Purification of a Membrane Transporter, the MexB Multidrug Resistance Protein
Published on: December 3, 2010
Molecular analysis of the multidrug transporter, P-glycoprotein
1Vertex Pharmaceuticals Incorporated, 130 Waverly Street, Cambridge, MA, 02139-4242, U.S.A., Germann@macnet.vpharm.com.
Abstract:
Inherent or acquired resistance of tumor cells to cytotoxic drugs represents a major limitation to the successful chemotherapeutic treatment of cancer. During the past three decades dramatic progress has been made in the understanding of the molecular basis of this phenomenon. Analyses of drug-selected tumor cells which exhibit simultaneous resistance to structurally unrelated anti-cancer drugs have led to the discovery of the human MDR1 gene product, P-glycoprotein, as one of the mechanisms responsible for multidrug resistance. Overexpression of this 170 kDa N-glycosylated plasma membrane protein in mammalian cells has been associated with ATP-dependent reduced drug accumulation, suggesting that P-glycoprotein may act as an energy-dependent drug efflux pump. P-glycoprotein consists of two highly homologous halves each of which contains a transmembrane domain and an ATP binding fold. This overall architecture is characteristic for members of the ATP-binding cassette or ABC superfamily of transporters. Cell biological, molecular genetic and biochemical approaches have been used for structure-function studies of P-glycoprotein and analysis of its mechanism of action. This review summarizes the current status of knowledge on the domain organization, topology and higher order structure of P-glycoprotein, the location of drug- and ATP binding sites within P-glycoprotein, its ATPase and drug transport activities, its possible functions as an ion channel, ATP channel and lipid transporter, its potential role in cholesterol biosynthesis, and the effects of phosphorylation on P-glycoprotein activity.
Insights
Tumor cells can resist chemotherapy due to multidrug resistance (MDR), often involving P-glycoprotein. This protein acts as an ATP-dependent efflux pump, reducing drug accumulation and limiting cancer treatment success.
Area of Science:
- Molecular Biology
- Biochemistry
- Cell Biology
Background:
- Acquired or inherent resistance in tumor cells to cytotoxic drugs hinders effective cancer chemotherapy.
- Multidrug resistance (MDR) is a significant challenge, characterized by simultaneous resistance to various anti-cancer drugs.
- The human MDR1 gene product, P-glycoprotein, has been identified as a key mechanism contributing to MDR.
Purpose of the Study:
- To review the current understanding of P-glycoprotein's structure and function in multidrug resistance.
- To elucidate the molecular mechanisms underlying P-glycoprotein's role as an ATP-dependent drug efflux pump.
- To explore P-glycoprotein's potential roles beyond drug transport, including ion and lipid transport and cholesterol biosynthesis.
Main Methods:
- Analysis of drug-selected tumor cells to identify resistance mechanisms.
- Structure-function studies utilizing cell biological, molecular genetic, and biochemical approaches.
- Review of existing literature on P-glycoprotein's domain organization, topology, and activity.
Main Results:
- P-glycoprotein, a 170 kDa N-glycosylated plasma membrane protein, is overexpressed in resistant cells, leading to reduced drug accumulation.
- P-glycoprotein functions as an ATP-dependent efflux pump, characteristic of the ATP-binding cassette (ABC) transporter superfamily.
- Studies have investigated drug and ATP binding sites, ATPase and transport activities, and potential roles in ion/lipid transport and phosphorylation effects.
Conclusions:
- P-glycoprotein is a critical factor in multidrug resistance, significantly impacting cancer chemotherapy outcomes.
- Understanding P-glycoprotein's structure and function is essential for developing strategies to overcome drug resistance.
- Further research into P-glycoprotein's diverse functions may reveal new therapeutic targets for cancer treatment.
Related Concept Videos
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
Carrier-Mediated Transport
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
The Significance of Membrane Transport
Transporters facilitate either an active or passive movement of solutes. They can allow a single-molecule transport down its...
ABC Transporters: Exporter
Drug Absorption Mechanism: Carrier-Mediated Membrane Transport
Facilitated diffusion is a passive process that utilizes human Solute Carrier (SLC) transporters. These transporters bind to the drug, undergo structural...
Pore Transport and Ion-Pair Transport
Pore transport, also known as convective transport, is a process where small molecules like urea, water, and sugars rapidly cross cell membranes as though there were channels or pores in the membrane. Although direct microscopic evidence is limited but the concept of pores or channels is widely accepted based on physiological evidence. Despite the lack of direct microscopic...

